No Data
No Data
ATyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
RBC Capital Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $16
Buy Rating Affirmed: ATyr Pharma's Positive Clinical Developments and Strategic Expansion
Express News | ATyr Pharma Completes Enrollment Of 268 Patients In Largest Ever Pulmonary Sarcoidosis Study; Topline Data Expected Q3 2025
ATyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
ATyr Pharma, Inc. (NASDAQ:ATYR) Is Largely Controlled by Institutional Shareholders Who Own 61% of the Company